Trial was the first to test a drug meant to delay or halt mental decline in people who have a genetic predisposition

Higher levels of everyday ageism associated with increased risk for negative physical and mental health outcomes

Percent of patients with conditions that had substantial or conclusive evidence of therapeutic value decreased from 2016 to 2020

Risks for new-onset psychiatric diagnoses and anxiety disorders, but not mood disorders, increased in early postacute phase

Addition of menthol to cigarettes also increases nicotine dependence in youth

Medicare spending higher for adults with a formal clinical diagnosis of dementia versus a positive screening for cognitive impairment

45.4 percent of biopsychosocial domain assessments reported more severe problems with drugs, 35.2 percent reported psychiatric problems

Gaps in strategic planning, financial preparedness, availability of services, and system coordination are reported

Standardized mortality ratio for suicide decreased from 2000 to 2016, but risk remains elevated, especially within first two years of diagnosis

However, despite declines from 2004 to 2020, substance use-related actions remain much higher than actions for physical, psychological impairment